1. Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial. (December 2020) Authors: Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Wijngaard, P.L.; Wright, R.S.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia. (December 2020) Authors: Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.A.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Landmesser, U.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗